clearside biomedical, inc. is a pharmaceuticals company located in 1220 old alpharetta rd., suite 300, alpharetta, ga, united states.
Company profile
Ticker
CLSD
Exchange
Website
CEO
George Lasezkay
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
CLSD stock data
Latest filings (excl ownership)
8-K
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
16 Apr 24
10-K
2023 FY
Annual report
12 Mar 24
8-K
Results of Operations and Financial Condition
12 Mar 24
8-K
Clearside Biomedical Announces Pricing of $15 Million Registered
8 Feb 24
424B5
Prospectus supplement for primary offering
8 Feb 24
8-K
Entry into a Material Definitive Agreement
1 Feb 24
8-K
Entry into a Material Definitive Agreement
28 Dec 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
13 Nov 23
8-K
Entry into a Material Definitive Agreement
3 Nov 23
Transcripts
CLSD
Earnings call transcript
2023 Q4
12 Mar 24
CLSD
Earnings call transcript
2023 Q3
13 Nov 23
CLSD
Earnings call transcript
2023 Q2
14 Aug 23
CLSD
Earnings call transcript
2023 Q1
11 May 23
CLSD
Earnings call transcript
2023 Q1
11 May 23
CLSD
Earnings call transcript
2022 Q4
9 Mar 23
CLSD
Earnings call transcript
2022 Q3
9 Nov 22
CLSD
Earnings call transcript
2022 Q2
9 Aug 22
CLSD
Earnings call transcript
2022 Q1
12 May 22
CLSD
Earnings call transcript
2021 Q4
11 Mar 22
Latest ownership filings
4
Anthony S Gibney
19 Apr 24
4
Anthony S Gibney
16 Apr 24
3
Anthony S Gibney
16 Apr 24
4
Ngai Hang Victor Chong
20 Mar 24
4
Ngai Hang Victor Chong
18 Mar 24
3
Ngai Hang Victor Chong
18 Mar 24
4
BRADFORD T WHITMORE
9 Feb 24
4
GEORGE M LASEZKAY
19 Jan 24
4
Charles A. Deignan
19 Jan 24
144
Notice of proposed sale of securities
19 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
17.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 48 |
Opened positions | 5 |
Closed positions | 13 |
Increased positions | 9 |
Reduced positions | 13 |
13F shares | Current |
---|---|
Total value | 6.44 bn |
Total shares | 13.25 mm |
Total puts | 76.00 k |
Total calls | 45.80 k |
Total put/call ratio | 1.7 |
Largest owners | Shares | Value |
---|---|---|
Hatteras Venture Advisors III | 3.06 mm | $3.70 mm |
Whitmore Bradford T | 2.36 mm | $0.00 |
Vanguard | 2.17 mm | $1.88 bn |
Carmignac Gestion | 2.13 mm | $1.86 bn |
BLK Blackrock | 763.23 k | $663.94 mm |
Geode Capital Management | 490.69 k | $426.97 mm |
Renaissance Technologies | 273.29 k | $238.00 k |
STT State Street | 193.36 k | $168.21 mm |
Bridgeway Capital Management | 175.60 k | $152.75 mm |
First Manhattan | 175.00 k | $152.23 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Apr 24 | Anthony S Gibney | Common Stock | Buy | Acquire P | No | No | 1.3 | 93,290 | 121.28 k | 100,000 |
17 Apr 24 | Anthony S Gibney | Common Stock | Buy | Acquire P | No | No | 1.25 | 6,710 | 8.39 k | 6,710 |
15 Apr 24 | Anthony S Gibney | Stock Option Common Stock | Grant | Acquire A | No | No | 1.29 | 45,000 | 58.05 k | 45,000 |
20 Mar 24 | Ngai Hang Victor Chong | Common Stock | Buy | Acquire P | No | No | 1.6 | 30,000 | 48.00 k | 30,000 |
18 Mar 24 | Ngai Hang Victor Chong | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.56 | 450,000 | 702.00 k | 450,000 |
News
Needham Reiterates Buy on Clearside Biomedical, Maintains $4 Price Target
11 Apr 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
27 Mar 24
12 Health Care Stocks Moving In Thursday's Intraday Session
14 Mar 24
HC Wainwright & Co. Reiterates Buy on Clearside Biomedical, Maintains $6 Price Target
14 Mar 24
JMP Securities Reiterates Market Outperform on Clearside Biomedical, Maintains $5 Price Target
13 Mar 24
Press releases
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
16 Apr 24
Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
2 Apr 24
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
18 Mar 24
Thinking about buying stock in Lexicon Pharmaceuticals, Cassava Sciences, Clearside Biomedical, Lantern Pharma, or ATAI Life Sciences?
13 Mar 24
Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024
29 Feb 24